|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wong FL and Miller JW: Centers for Disease
Control and Prevention's National Breast and Cervical Cancer Early
Detection Program: Increasing Access to Screening. J Womens Health
(Larchmt). 28:427–431. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cancer Genome Atlas Research Network;
Albert Einstein College of Medicine; Analytical Biological
Services; Integrated genomic and molecular characterization of
cervical cancer. Nature 543: 378-384, 2017.
|
|
4
|
Marth C, Landoni F, Mahner S, McCormack M,
Gonzalez-Martin A, Colombo N and Committee EG: Cervical cancer:
ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 28:iv72–iv83. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Reesink-Peters N, van der Velden J, Ten
Hoor KA, Boezen HM, de Vries EG, Schilthuis MS, Mourits MJ, Nijman
HW, Aalders JG, Hollema H, et al: Preoperative serum squamous cell
carcinoma antigen levels in clinical decision making for patients
with early-stage cervical cancer. J Clin Oncol. 23:1455–1462.
2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Jonckheere N and Van Seuningen I:
Integrative analysis of the cancer genome atlas and cancer cell
lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20
signature is associated with poor survival in human carcinomas. J
Transl Med. 16(259)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hollingsworth MA and Swanson BJ: Mucins in
cancer: Protection and control of the cell surface. Nat Rev Cancer.
4:45–60. 2004.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Rao CV, Janakiram NB and Mohammed A:
Molecular pathways: Mucins and drug delivery in cancer. Clin Cancer
Res. 23:1373–1378. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Das S and Batra SK: Understanding the
unique attributes of MUC16 (CA125): Potential implications in
targeted therapy. Cancer Res. 75:4669–4674. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lakshmanan I, Salfity S, Seshacharyulu P,
Rachagani S, Thomas A, Das S, Majhi PD, Nimmakayala RK, Vengoji R,
Lele SM, et al: MUC16 regulates TSPYL5 for lung cancer cell growth
and chemoresistance by suppressing p53. Clin Cancer Res.
23:3906–3917. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Streppel MM, Vincent A, Mukherjee R,
Campbell NR, Chen SH, Konstantopoulos K, Goggins MG, Van Seuningen
I, Maitra A and Montgomery EA: Mucin 16 (cancer antigen 125)
expression in human tissues and cell lines and correlation with
clinical outcome in adenocarcinomas of the pancreas, esophagus,
stomach, and colon. Hum Pathol. 43:1755–1763. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gubbels JA, Felder M, Horibata S, Belisle
JA, Kapur A, Holden H, Petrie S, Migneault M, Rancourt C, Connor
JP, et al: MUC16 provides immune protection by inhibiting synapse
formation between NK and ovarian tumor cells. Mol Cancer.
9(11)2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Patankar MS, Jing Y, Morrison JC, Belisle
JA, Lattanzio FA, Deng Y, Wong NK, Morris HR, Dell A and Clark GF:
Potent suppression of natural killer cell response mediated by the
ovarian tumor marker CA125. Gynecol Oncol. 99:704–713.
2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Fan K, Yang C, Fan Z, Huang Q, Zhang Y,
Cheng H, Jin K, Lu Y, Wang Z, Luo G, et al: MUC16 C
terminal-induced secretion of tumor-derived IL-6 contributes to
tumor-associated Treg enrichment in pancreatic cancer. Cancer Lett.
418:167–175. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Li X, Pasche B, Zhang W and Chen K:
Association of MUC16 mutation with tumor mutation load and outcomes
in patients with gastric cancer. JAMA Oncol. 4:1691–1698.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hu J and Sun J: MUC16 mutations improve
patients' prognosis by enhancing the infiltration and antitumor
immunity of cytotoxic T lymphocytes in the endometrial cancer
microenvironment. Oncoimmunology. 7(e1487914)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Aggarwal P and Kehoe S: Serum tumour
markers in gynaecological cancers. Maturitas. 67:46–53.
2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lee YY, Kim TJ, Kim JY, Choi CH, Do IG,
Song SY, Sohn I, Jung SH, Bae DS, Lee JW, et al: Genetic profiling
to predict recurrence of early cervical cancer. Gynecol Oncol.
131:650–654. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Scotto L, Narayan G, Nandula SV,
Arias-Pulido H, Subramaniyam S, Schneider A, Kaufmann AM, Wright
JD, Pothuri B, Mansukhani M, et al: Identification of copy number
gain and overexpressed genes on chromosome arm 20q by an
integrative genomic approach in cervical cancer: Potential role in
progression. Genes Chromosomes Cancer. 47:755–765. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA pan-cancer clinical data resource to
drive high-quality survival outcome analytics. Cell.
173:400–416.e11. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14(7)2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mayakonda A, Lin DC, Assenov Y, Plass C
and Koeffler HP: Maftools: Efficient and comprehensive analysis of
somatic variants in cancer. Genome Res. 28:1747–1756.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Johnson KR, Liauw W and Lassere MN:
Evaluating surrogacy metrics and investigating approval decisions
of progression-free survival (PFS) in metastatic renal cell cancer:
A systematic review. Ann Oncol. 26:485–496. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Punt S, Houwing-Duistermaat JJ, Schulkens
IA, Thijssen VL, Osse EM, de Kroon CD, Griffioen AW, Fleuren GJ,
Gorter A and Jordanova ES: Correlations between immune response and
vascularization qRT-PCR gene expression clusters in squamous
cervical cancer. Mol Cancer. 14(71)2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Heeren AM, Koster BD, Samuels S, Ferns DM,
Chondronasiou D, Kenter GG, Jordanova ES and de Gruijl TD: High and
interrelated rates of PD-L1+CD14+
antigen-presenting cells and regulatory T cells mark the
microenvironment of metastatic lymph nodes from patients with
cervical cancer. Cancer Immunol Res. 3:48–58. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cui JH, Lin KR, Yuan SH, Jin YB, Chen XP,
Su XK, Jiang J, Pan YM, Mao SL, Mao XF, et al: TCR repertoire as a
novel indicator for immune monitoring and prognosis assessment of
patients with cervical cancer. Front Immunol.
9(2729)2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Mehnert JM, Panda A, Zhong H, Hirshfield
K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L,
Kaufman HL, et al: Immune activation and response to pembrolizumab
in POLE-mutant endometrial cancer. J Clin Invest. 126:2334–2340.
2016.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Choi M, Kadara H, Zhang J, Parra ER,
Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J,
Chow C, et al: Mutation profiles in early-stage lung squamous cell
carcinoma with clinical follow-up and correlation with markers of
immune function. Ann Oncol. 28:83–89. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
McFarland CD, Yaglom JA, Wojtkowiak JW,
Scott JG, Morse DL, Sherman MY and Mirny LA: The damaging effect of
passenger mutations on cancer progression. Cancer Res.
77:4763–4772. 2017.PubMed/NCBI View Article : Google Scholar
|
